Indolent Non-Hodgkin Lymphoma — Trials

Indolent Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 212
Recruiting: 104
Ph III recruiting: 4
Growth YoY: +51.7%
Industry share: 20%
Top sponsor: City of Hope Medical Center
Termination share: 36.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (150)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05172700	Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer	approved for marketing	—	—	Loxo Oncology, Inc.INDUSTRY	0	Dec 18, 2024	clinicaltrials

Data updated 22 days agoSource updated Dec 18, 2024source: clinicaltrials